An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma... by Kapoor, Prashant, Nathwani, Nitya, Jelinek, Tomas, Pour, Ludek, Perrot, Aurore, Dimopoulos, Meletios‐Athanasios, Huang, Shang‐Yi, Spicka, Ivan, Chhabra, Saurabh, Lichtman, Eben, Mateos, Maria‐Victoria, Kanagavel, Dheepak, Zhao, Liang, Guillemin‐Paveau, Helene, Macé, Sandrine, Velde, Helgi, Richardson, Paul G.

Get full text

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study by Sunami, Kazutaka, Suzuki, Kenshi, Ri, Masaki, Matsumoto, Morio, Shimazaki, Chihiro, Asaoku, Hideki, Shibayama, Hirohiko, Ishizawa, Kenichi, Takamatsu, Hiroyuki, Ikeda, Takashi, Maruyama, Dai, Kaneko, Hitomi, Uchiyama, Michihiro, Kiguchi, Toru, Iyama, Satoshi, Murakami, Hirokazu, Takahashi, Keishiro, Tada, Keisuke, Macé, Sandrine, Guillemin‐Paveau, Hélène, Iida, Shinsuke

Get full text

779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors by Gutierrez, Martin, Garralda, Elena, Calvo, Emiliano, Dongen, Marloes van, Eskens, Ferry, Finlay, Morgan, Menas, Fatima, Zhu, Chen, Wu, Meijing, Guillemin-Paveau, Helene, Abbadessa, Giovanni, Perez, Raymond, Yildirim, Ozlem, Naing, Aung

Get full text

782-I Phase I dose escalation of SAR445710, a PDL1-IL15 targeted cytokine in metastatic and/or advanced solid tumors by Luke, Jason, Olszanski, Anthony J, Rosen, Lee, Tarhini, Ahmad A, Baakili, Adyb, Wagenaar, Timothy, Zhu, Chen, Guillemin-Paveau, Helene, Wu, Meijing, Perez, Raymond, Abbadessa, Giovanni, Fountzilas, Christos

Get full text